The importance of ancestry to understanding tumor mutation burden in cancer
- PMID: 36179683
- DOI: 10.1016/j.ccell.2022.09.004
The importance of ancestry to understanding tumor mutation burden in cancer
Abstract
In the current issue of Cancer Cell, Nassar and colleagues find that in solid tumors, tumor-only sequencing leads to an overestimate of the biomarker tumor mutation burden (TMB), particularly in patients of African or Asian ancestry. Correction of the TMB estimate improves the correlation between TMB and response to immunotherapy.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining Human Leukocyte Antigen loss of heterozygosity (PCT/GB2018/052004), and predicting survival rates of patients with cancer (PCT/GB2020/050221). A.S. was previously an employee of, and still holds stock in, Merck, Inc. A.S. is currently an employee of Generate Biomedicines.
Comment on
-
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.Cancer Cell. 2022 Oct 10;40(10):1161-1172.e5. doi: 10.1016/j.ccell.2022.08.022. Epub 2022 Sep 29. Cancer Cell. 2022. PMID: 36179682 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical